Paxman announced a team of clinicians and scientists from the National University Cancer Institute, Singapore (NCIS) at the National University Hospital (NUH) and the N.1 Institute for Health at the National University of Singapore (NUS) have partnered Paxman Coolers Ltd. (UK) (Paxman) to develop a device that may prevent or reduce numbness and pain caused by certain types of anti-cancer therapy[1]. Chemotherapy- induced peripheral neuropathy (CIPN) is a severe side-effect of chemotherapy drugs called taxanes, which are used to treat common cancers such as breast, lung, ovarian and stomach cancer. CIPN affects about 1.4 million cancer patients globally every year[2]. In collaboration with Paxman, the Singapore research team from NUHS comprising clinicians and researchers from the Department of Haematology-Oncology at NCIS and NUH, and the N.1 Institute for Health at NUS are developing a portable limb cryocompression device specifically targeting prevention of CIPN in cancer patients. The team has studied various proof of concept aspects of the cryocompression technology, over the past eight years[3], previously supported by the National Health Innovation Centre Singapore (NHIC) through its Innovation to Develop grant. Working together as a team since 2019, Paxman, global leaders in scalp cooling for prevention of chemo-induced hair loss, was identified as the ideal commercialisation partner for the project. The research team has been awarded a translational grant of $1.57M SGD from the National Research Foundation (NRF) Central Gap Fund in May 2021, which will be administered by NHIC. Pilot studies will commence in second quarter 2022 to investigate the device in healthy volunteers, and cancer patients undergoing CIPN- causing chemotherapy. The efficacy of prevention will be monitored using various clinical and patient- reported outcomes.